Drug Survival and Predictors of Systemic Treatment Outcome in Atopic Dermatitis: Data From a Nationwide Swedish Cohort
DOI:
https://doi.org/10.2340/actadv.v105.43464Keywords:
atopic dermatitis, dupilumab, Janus kinase inhibitors, Survival AnalysisAbstract
Real-world data on the drug survival of established and emerging treatment options in atopic dermatitis provide a comprehensive measure of the efficacy and tolerability of these interventions, which may enable improvements in clinical management. This study aimed to describe the drug survival, with associated predictors, of treatment with abrocitinib, baricitinib, cyclosporine, dupilumab, methotrexate, tralokinumab, and upadacitinib among patients with atopic dermatitis in Sweden who were recruited into the multicentre prospective SwedAD cohort between January 2017 and April 2024. A total of 1,194 patients were included with a total of 1,486 treatment episodes. The 2-year drug survival probability was 14.2% for baricitinib (treatment episodes, n = 30), 12.2% for cyclosporine (n = 40), 79.7% for dupilumab (n = 1,026), 45.4% for methotrexate (n = 260), and 46.0% for upadacitinib (n = 89). Two-year follow-up data were not available for abrocitinib (n = 23) or tralokinumab (n = 18). All drugs were compared with the most used conventional systemic treatment at study baseline, methotrexate, using Cox regression. Only dupilumab showed a significantly lower hazard rate of drug discontinuation. In conclusion, dupilumab therapy demonstrated longer drug survival than methotrexate in atopic dermatitis. The impact of national treatment guidelines and time since drug approval should be considered when interpreting the results.
Downloads
References
Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet 2020; 396: 345–360. DOI: https://doi.org/10.1016/S0140-6736(20)31286-1
Gånemo A, Svensson A, Lindberg M, Wahlgren CF. Quality of life in Swedish children with eczema. Acta Derm Venereol 2007; 87: 345–349. DOI: https://doi.org/10.2340/00015555-0245
Bylund S, Kobyletzki LB, Svalstedt M, Svensson Å. Prevalence and incidence of atopic dermatitis: a systematic review. Acta Derm Venereol 2020; 100: adv00160. DOI: https://doi.org/10.2340/00015555-3510
Tian J, Zhang D, Yang Y, Huang Y, Wang L, Yao X, et al. Global epidemiology of atopic dermatitis: a comprehensive systematic analysis and modelling study. Br J Dermatol 2023; 190: 55–61. DOI: https://doi.org/10.1093/bjd/ljad339
Augustin M, Misery L, von Kobyletzki L, Armario-Hita JC, Mealing S, Redding M. Unveiling the true costs and societal impacts of moderate-to-severe atopic dermatitis in Europe. J Eur Acad Dermatol Venereol 2022; 36 Suppl 7: 3–16. DOI: https://doi.org/10.1111/jdv.18168
Wollenberg A, Kinberger M, Arents B, Aszodi N, Avila Valle G, Barbarot S, et al. European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy. J Eur Acad Dermatol Venereol 2022; 36: 1409–1431. DOI: https://doi.org/10.1111/jdv.18345
Seegräber M, Srour J, Walter A, Knop M, Wollenberg A. Dupilumab for treatment of atopic dermatitis. Expert Rev Clin Pharmacol 2018; 11: 467–474. DOI: https://doi.org/10.1080/17512433.2018.1449642
Gooderham MJ, Hong HC, Eshtiaghi P, Papp KA. Dupilumab: a review of its use in the treatment of atopic dermatitis. J Am Acad Dermatol 2018; 78: S28–S36. DOI: https://doi.org/10.1016/j.jaad.2017.12.022
Popovic B, Breed J, Rees DG, Gardener MJ, Vinall LM, Kemp B, et al. Structural characterisation reveals mechanism of IL-13-neutralising monoclonal antibody tralokinumab as inhibition of binding to IL-13Rα1 and IL-13Rα2. J Mol Biol 2017; 429: 208–219. DOI: https://doi.org/10.1016/j.jmb.2016.12.005
Potestio L, Patruno C, Napolitano M. Efficacy and safety of tralokinumab in real life: possible predictive rapid response factors. Dermatitis 2024; 35: S77–S80. DOI: https://doi.org/10.1089/derm.2023.0261
van den Reek J, Kievit W, Gniadecki R, Goeman JJ, Zweegers J, van de Kerkhof PCM, et al. Drug survival studies in dermatology: principles, purposes, and pitfalls. J Invest Dermatol 2015; 135: 1–5. DOI: https://doi.org/10.1038/jid.2015.171
Alsterholm M, Svedbom A, Anderson CD, Holm Sommar L, Ivert LU, Josefson A, et al. Establishment and utility of SwedAD: a nationwide Swedish Registry for patients with atopic dermatitis receiving systemic pharmacotherapy. Acta Derm Venereol 2023; 103: adv7312. DOI: https://doi.org/10.2340/actadv.v103.7312
Schram ME, Spuls PI, Leeflang MM, Lindeboom R, Bos JD, Schmitt J. EASI (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy 2012; 67: 99–106. DOI: https://doi.org/10.1111/j.1398-9995.2011.02719.x
Yosipovitch G, Reaney M, Mastey V, Eckert L, Abbé A, Nelson L, et al. Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol 2019; 181: 761–769. DOI: https://doi.org/10.1111/bjd.17744
Basra MK, Salek MS, Camilleri L, Sturkey R, Finlay AY. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology 2015; 230: 27–33. DOI: https://doi.org/10.1159/000365390
Hengartner MP, Plöderl M. Estimates of the minimal important difference to evaluate the clinical significance of antidepressants in the acute treatment of moderate-to-severe depression. BMJ Evid Based Med 2022; 27: 69–73. DOI: https://doi.org/10.1136/bmjebm-2020-111600
Spekhorst LS, Ariëns LFM, van der Schaft J, Bakker DS, Kamsteeg M, Oosting AJ, et al. Two-year drug survival of dupilumab in a large cohort of difficult-to-treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: results from the BioDay registry. Allergy 2020; 75: 2376–2379. DOI: https://doi.org/10.1111/all.14324
Barei F, Calzari P, Valtellini L, Chiei Gallo A, Perego G, Tavecchio S, et al. Five-year real-world drug survival of dupilumab in severe atopic dermatitis and associate predictors. J Dermatolog Treat 2024; 35: 2404718. DOI: https://doi.org/10.1080/09546634.2024.2404718
Spekhorst LS, de Graaf M, Zuithoff NPA, van den Reek J, Kamsteeg M, Boesjes CM, et al. Dupilumab drug survival and associated predictors in patients with moderate to severe atopic dermatitis: long-term results from the daily practice BioDay Registry. JAMA Dermatol 2022; 158: 1048–1056. DOI: https://doi.org/10.1001/jamadermatol.2022.3014
Pezzolo E, Ortoncelli M, Ferrucci SM, Guanti MB, Schena D, Napolitano M, et al. Drug survival of upadacitinib and predicting factors of discontinuation in adult patients affected by moderate-to-severe atopic dermatitis: an Italian multicenter analysis. J Clin Med 2024; 13. DOI: https://doi.org/10.3390/jcm13020553
Dal Bello G, Maurelli M, Schena D, Girolomoni G, Gisondi P. Drug survival of dupilumab compared to cyclosporin in moderate-to-severe atopic dermatitis patients. Dermatol Ther 2020; 33: e13979. DOI: https://doi.org/10.1111/dth.13979
Pezzolo E, Schena D, Gambardella A, Rossi M, Barei F, Calzavara Pinton P, et al. Survival, efficacy and safety of tralokinumab after 32 and 52 weeks of treatment for moderate-to-severe atopic dermatitis in adults: a multicentre real-world study. J Eur Acad Dermatol Venereol 2024; 38: e11–e13. DOI: https://doi.org/10.1111/jdv.19382
Torres T, Yeung J, Prajapati V, Ribero S, Balato A, Valerio Marzano A, et al. Drug survival of dupilumab, tralokinumab and upadacitinib in patie)nts with atopic dermatitis: an international, real-world comparative study. J Eur Acad Dermatol Venereol 2025; 10.1111/jdv.20581. DOI: https://doi.org/10.1111/jdv.20581
Müller S, Maintz L, Bieber T. Treatment of atopic dermatitis: recently approved drugs and advanced clinical development programs. Allergy 2024; 79: 1501–1515. DOI: https://doi.org/10.1111/all.16009
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Pontus O. Jonsson, Mahsa Tayefi, Axel Svedbom, Maria Bradley, Emma K. Johansson
This work is licensed under a Creative Commons Attribution 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
